**MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by** *LMNA* **Mutations**

Antoine Muchir1,2

*1Department of Medicine, 2Department of Pathology and Cell Biology, College of Physicians and Surgeons, Columbia University, New York, NY USA* 

### **1. Introduction**

96 Advances in Protein Kinases

Zacharioudaki, V.; Androulidaki, A.; Arranz, A.; Vrentzos, G.; Margioris, AN. & Tsatsanis,

blood. *Bioorg Med Chem Lett.* Vol. 19, 3485-3488.

IRAK-M expression. *J Immunol.* 182, 6444- 6451.

Telliez, JB.; Cui, J. & Lin LL. (2009). Selective inhibitors of tumor progression loci-2 (Tpl2) kinase with potent inhibition of TNF-alpha production in human whole

C. (2009). Adiponectin promotes endotoxin tolerance in macrophages by inducing

Inherited dilated cardiomyopathies are a major cause of heart disease in human, often with an onset in adolescence or early adult life. Despite technological advances that foster early diagnosis and alleviation of some symptoms, inherited dilated cardiomyopathies remains a critical unsolved problem for public health. The recent years provided some clues to explain the pathogenesis of inherited dilated cardiomyopathies, which might open new and encouraging perspectives for clinical trials.

### **2.** *LMNA* **dilated cardiomyopathy**

Cardiomyopathy is an anatomic and pathologic condition associated with muscle dysfunction of the heart. Dilated cardiomyopathy, the most common form, is characterized by an increase in both myocardial mass and volume, which compromises cardiac contractility and ultimately results in reduced left ventricular function (Luk et al. 2008). Dilated cardiomyopathy is the third leading cause of heart failure in the United States behind coronary artery disease and hypertension. Genetically inherited forms of dilated cardiomyopathy have been identified in 30% of patients presenting with this disease (Michels et al., 1992). Many other acquired conditions may result in an identical clinical presentation and pathological function, which include alcohol-induced cardiomyopathy, hypertension, chronic anemia, ischemic cardiomyopathy, valvular diseases and viral myocarditis (Maron et al., 2006).

Inherited dilated cardiomyopathies are caused by mutations in genes that encode components of a wide variety of cellular components and pathways, including the nuclear envelope, contractile apparatus and the force transduction apparatus (Morita et al., 2005). The generation of contractile force by the sarcomere and its transmission to the extracellular matrix are the fundamental functions of cardiac cells. Inadequate performance in either components of this structural cellular network leads to cardiac remodeling and ultimately to dilated cardiomyopathy. Defects in generating force are typically due to a loss of integrity of the sarcomere unit. Mutations in the loci coding for -cardiac myosin heavy chain, actin (Olson et al., 1998) and cardiac troponin T (Li et al., 2001) have been identified to disrupt

MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by *LMNA* Mutations 99

The pathogenesis of *LMNA* dilated cardiomyopathy remains a puzzle in medical genetics. Mouse models have been extremely helpful in deciphering critical mechanisms, which could partially explain the pathogenesis of the disease as well as for proposing potential innovative pharmacological therapies. Using a murine model of *LMNA* dilated cardiomyopathy, we recently brought some insights into the molecular pathogenesis of this disease, which have paved the way to potential therapies. To approach the issue of understanding the pathogenesis of *LMNA* dilated cardiomyopathy, we studied the transcriptome from hearts of *Lmna* H222P mice (a mouse model of *LMNA* dilated cardiomyopathy), using the Affymetrix® array technology. Male *Lmna* H222P mice develop cardiac chamber dilation, decreased left ventricle ejection fraction and hypokinesis detectable by echocardiography at 8 to 10 weeks of age (Arimura et al. 2005). To avoid interference caused by fibrotic cells and nonspecific tissue damage in hearts from older *Lmna* H222P mice, we initially analyzed samples from mice at 10 weeks of age where there were no detectable cardiac histological abnormalities. We analyzed gene ontology terms applied to genes, to identify functional classes of genes differentially expressed in hearts of *Lmna* H222P mice compared with those expressed in controls. Analysis using functional class scoring improves sensitivity by statistically evaluating genes in biologically meaningful groups. Genes encoding proteins in mitogen-activated protein kinase (MAPK) signaling pathway demonstrated significantly altered expression in hearts of *Lmna* H222P mice (Muchir et al. 2007) (Figure 1). Because enhanced activity of the Extracellular signalregulated kinase1/2 (ERK1/2), a branch of MAPK signaling pathways, has been formerly shown to be causing cardiomyopathy, we focused subsequent experiments on analyzing this signaling in tissues form *Lmna* H222P mice and in cultured cells. We then demonstrated an aberrant activation of ERK1/2 signaling in hearts from *Lmna* H222P mice, as early as 4 weeks of age (Muchir et al. 2007). Our work proved that the activation of ERK1/2 signaling pathway preceded the cardiac dysfunction of *Lmna* H222P mice and that it is a consequence

**4. Pathogenesis of** *LMNA* **dilated cardiomyopathy** 

of alterations in A-type lamins and not secondary to non-specific affects.

MAPK signaling pathways are major information highways from extracellular mitogens, growth factors and cytokines at the cell surface to the nucleus to control gene expression (Davis, 1993). These signaling pathways control complex cellular programs, such as embryogenesis, differentiation, proliferation and cell death, in addition to short-term changes required for mechanical stress response and acute hormonal responses. The output of these pathways is transduced via MAPK family members that phosphorylate and regulate a wide array of substrates including transcription factors, cytoskeletal elements and other protein kinases (Seger & Krebs, 1995). Stimulation of many receptor classes can activate ERK1/2 including receptors with intrinsic tyrosine kinase activity, cytokine receptors and G-protein-coupled receptors (GPCR), including those coupling via G-proteins of the Gq/11, Gi/o and Gs family. In the heart, ERK1/2 stimulation has been shown by fibroblast growth factor, insulin-like growth factor-1, estrogen, neuregulin-1, atrial natriuretic peptide, 1- and -adrenoceptor agonists. Moreover, cardiac ERK1/2 can be

activated independently than GPCR receptors, via mechanical stress, osmotic shock.

**5. MEK-ERK signaling pathway** 

force generation (Kamisago et al, 2000). Defects in the force transmission occur when there is impairment in the propagation of force from the sarcomere to the sarcolemma (Schonberger et al. 2001). Mutations in -tropomyosin (Olson et al. 2001), dystrophin (Muntoni et al., 1993), desmin (Li et al 1999) and -sarcoglycan (Tsubata et al. 2000) have been identified to disrupt force transmission.

Among the causing genes, *LMNA* mutations encoding proteins of the inner nuclear membrane, have also been found associated to dilated cardiomyopathy (Fatkin et al. 1999). This finding raises the possibility that the nuclear envelope may play an important function as mechanosensor in cardiomyocyte (Nikolova et al. 2004, Lammerding et al. 2004). *LMNA* mutations appear to be responsible for approximately 8% of cases of inherited cardiomyopathy (Taylor et al., 2003), which strongly suggest that *LMNA* may be the most prevalent dilated cardiomyopathy gene. *LMNA* dilated cardiomyopathy is characterized by cardiac dilatation and impaired systolic function. In addition, affected patients exhibit early conduction defects before the left ventricular dysfunction and dilatation stages. The onset of symptoms in *LMNA* dilated cardiomyopathy is variable, ranging from the first to sixth decade of life and occurring most frequently in the third decade (mean age = 38 years) (Ben Yaou et al., 2006). There are high rates of life-threatening arrhythmias (abnormal electrical conduction), gradually worsening and leading to sudden death (Sanna et al. 2003). *LMNA* dilated cardiomyopathy has a more aggressive course than other inherited dilated cardiomyopathies. While sudden death from arrhythmias may be prevented by implantation of a pacemaker and/or implantable defibrillator, the progressive heart failure eventually becomes resistant to treatment (Golzio et al. 2007, van Berlo et al. 2005, Meune et al., 2006). No drugs are curative and heart transplantation is frequently necessary.

### **3. A-type nuclear lamins**

*LMNA*, located on human chromosome 1q21.2-21.3, encodes A-type lamins. Lamin A and lamin C are the major A-type lamins expressed in somatic cells. They arise via alternative splicing of pre-mRNA encoded by exon 10 (Lin & Worman 1993). Lamin A is synthesized as a precursor, prelamin A, which has a unique C-terminal amino acid tail that triggers a series of enzymatic reactions to yield lamin A. Two other genes in the mammalian genome, *LMNB1* and *LMNB2*, respectively encode lamins B1 and B2. Lamins A and C are widely expressed in most differentiated somatic cells but lacking from early embryos and some undifferentiated cells whereas lamins B1 and B2 are expressed in all or most somatic cells. However, there are little data and no systemic studies on the differences in the relative amounts of lamins A, C, B1 and B2 expression. Lamins are intermediate filaments proteins that polymerize to form the nuclear lamina, a fibrous meshwork underlining the inner nuclear membrane of most eukaryotic cells (Fisher et al. 1986, McKeon et al. 1986, Aebi et al. 1986). The nuclear lamina is attached to the inner nuclear membrane via interactions with integral proteins and to the chromatin. More recently, it has been demonstrated that lamin A/C also have interactions with the cytoskeleton, through a multi-protein complex called "LINC" (LInker of Nucleoskeleton and Cytoskeleton) (Stewart et al. 2007). One function of the lamina is to provide structural support to the nucleus. Nuclear lamins have also been implicated in processes such as chromatin organization, gene regulation, DNA replication and RNA splicing (Dechat et al. 2008). However, the specific mechanistic roles of lamins in these processes, particularly in a cell or tissue type-specific context, remain obscure.

### **4. Pathogenesis of** *LMNA* **dilated cardiomyopathy**

98 Advances in Protein Kinases

force generation (Kamisago et al, 2000). Defects in the force transmission occur when there is impairment in the propagation of force from the sarcomere to the sarcolemma (Schonberger et al. 2001). Mutations in -tropomyosin (Olson et al. 2001), dystrophin (Muntoni et al., 1993), desmin (Li et al 1999) and -sarcoglycan (Tsubata et al. 2000) have been identified to

Among the causing genes, *LMNA* mutations encoding proteins of the inner nuclear membrane, have also been found associated to dilated cardiomyopathy (Fatkin et al. 1999). This finding raises the possibility that the nuclear envelope may play an important function as mechanosensor in cardiomyocyte (Nikolova et al. 2004, Lammerding et al. 2004). *LMNA* mutations appear to be responsible for approximately 8% of cases of inherited cardiomyopathy (Taylor et al., 2003), which strongly suggest that *LMNA* may be the most prevalent dilated cardiomyopathy gene. *LMNA* dilated cardiomyopathy is characterized by cardiac dilatation and impaired systolic function. In addition, affected patients exhibit early conduction defects before the left ventricular dysfunction and dilatation stages. The onset of symptoms in *LMNA* dilated cardiomyopathy is variable, ranging from the first to sixth decade of life and occurring most frequently in the third decade (mean age = 38 years) (Ben Yaou et al., 2006). There are high rates of life-threatening arrhythmias (abnormal electrical conduction), gradually worsening and leading to sudden death (Sanna et al. 2003). *LMNA* dilated cardiomyopathy has a more aggressive course than other inherited dilated cardiomyopathies. While sudden death from arrhythmias may be prevented by implantation of a pacemaker and/or implantable defibrillator, the progressive heart failure eventually becomes resistant to treatment (Golzio et al. 2007, van Berlo et al. 2005, Meune et

al., 2006). No drugs are curative and heart transplantation is frequently necessary.

these processes, particularly in a cell or tissue type-specific context, remain obscure.

*LMNA*, located on human chromosome 1q21.2-21.3, encodes A-type lamins. Lamin A and lamin C are the major A-type lamins expressed in somatic cells. They arise via alternative splicing of pre-mRNA encoded by exon 10 (Lin & Worman 1993). Lamin A is synthesized as a precursor, prelamin A, which has a unique C-terminal amino acid tail that triggers a series of enzymatic reactions to yield lamin A. Two other genes in the mammalian genome, *LMNB1* and *LMNB2*, respectively encode lamins B1 and B2. Lamins A and C are widely expressed in most differentiated somatic cells but lacking from early embryos and some undifferentiated cells whereas lamins B1 and B2 are expressed in all or most somatic cells. However, there are little data and no systemic studies on the differences in the relative amounts of lamins A, C, B1 and B2 expression. Lamins are intermediate filaments proteins that polymerize to form the nuclear lamina, a fibrous meshwork underlining the inner nuclear membrane of most eukaryotic cells (Fisher et al. 1986, McKeon et al. 1986, Aebi et al. 1986). The nuclear lamina is attached to the inner nuclear membrane via interactions with integral proteins and to the chromatin. More recently, it has been demonstrated that lamin A/C also have interactions with the cytoskeleton, through a multi-protein complex called "LINC" (LInker of Nucleoskeleton and Cytoskeleton) (Stewart et al. 2007). One function of the lamina is to provide structural support to the nucleus. Nuclear lamins have also been implicated in processes such as chromatin organization, gene regulation, DNA replication and RNA splicing (Dechat et al. 2008). However, the specific mechanistic roles of lamins in

disrupt force transmission.

**3. A-type nuclear lamins** 

The pathogenesis of *LMNA* dilated cardiomyopathy remains a puzzle in medical genetics. Mouse models have been extremely helpful in deciphering critical mechanisms, which could partially explain the pathogenesis of the disease as well as for proposing potential innovative pharmacological therapies. Using a murine model of *LMNA* dilated cardiomyopathy, we recently brought some insights into the molecular pathogenesis of this disease, which have paved the way to potential therapies. To approach the issue of understanding the pathogenesis of *LMNA* dilated cardiomyopathy, we studied the transcriptome from hearts of *Lmna* H222P mice (a mouse model of *LMNA* dilated cardiomyopathy), using the Affymetrix® array technology. Male *Lmna* H222P mice develop cardiac chamber dilation, decreased left ventricle ejection fraction and hypokinesis detectable by echocardiography at 8 to 10 weeks of age (Arimura et al. 2005). To avoid interference caused by fibrotic cells and nonspecific tissue damage in hearts from older *Lmna* H222P mice, we initially analyzed samples from mice at 10 weeks of age where there were no detectable cardiac histological abnormalities. We analyzed gene ontology terms applied to genes, to identify functional classes of genes differentially expressed in hearts of *Lmna* H222P mice compared with those expressed in controls. Analysis using functional class scoring improves sensitivity by statistically evaluating genes in biologically meaningful groups. Genes encoding proteins in mitogen-activated protein kinase (MAPK) signaling pathway demonstrated significantly altered expression in hearts of *Lmna* H222P mice (Muchir et al. 2007) (Figure 1). Because enhanced activity of the Extracellular signalregulated kinase1/2 (ERK1/2), a branch of MAPK signaling pathways, has been formerly shown to be causing cardiomyopathy, we focused subsequent experiments on analyzing this signaling in tissues form *Lmna* H222P mice and in cultured cells. We then demonstrated an aberrant activation of ERK1/2 signaling in hearts from *Lmna* H222P mice, as early as 4 weeks of age (Muchir et al. 2007). Our work proved that the activation of ERK1/2 signaling pathway preceded the cardiac dysfunction of *Lmna* H222P mice and that it is a consequence of alterations in A-type lamins and not secondary to non-specific affects.

### **5. MEK-ERK signaling pathway**

MAPK signaling pathways are major information highways from extracellular mitogens, growth factors and cytokines at the cell surface to the nucleus to control gene expression (Davis, 1993). These signaling pathways control complex cellular programs, such as embryogenesis, differentiation, proliferation and cell death, in addition to short-term changes required for mechanical stress response and acute hormonal responses. The output of these pathways is transduced via MAPK family members that phosphorylate and regulate a wide array of substrates including transcription factors, cytoskeletal elements and other protein kinases (Seger & Krebs, 1995). Stimulation of many receptor classes can activate ERK1/2 including receptors with intrinsic tyrosine kinase activity, cytokine receptors and G-protein-coupled receptors (GPCR), including those coupling via G-proteins of the Gq/11, Gi/o and Gs family. In the heart, ERK1/2 stimulation has been shown by fibroblast growth factor, insulin-like growth factor-1, estrogen, neuregulin-1, atrial natriuretic peptide, 1- and -adrenoceptor agonists. Moreover, cardiac ERK1/2 can be activated independently than GPCR receptors, via mechanical stress, osmotic shock.

MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by *LMNA* Mutations 101

analyzed the mice at 20 weeks (Wu et al. 2011). Treatment with PD98059 prevented left ventricular end-systolic dilatation, increased ejection fraction (Table 1), blocked increased cardiac expression of RNAs encoding natriuretic peptide precursors and reversed the induction of elements of the "fetal gene program" compared to placebo-treated mice. As significant cardiac fibrosis occurs in end-stage dilated cardiomyopathy, particularly *LMNA*  dilated cardiomyopathy, we also examined cardiac fibrosis after treatment. *Lmna* H222P mice treated with PD98059 had a lower degree of cardiac fibrosis than the *Lmna* H222P mice treated with placebo. Overall, this work showed that inhibiting ERK1/2 signaling had positive effects on cardiac biochemistry and physiology in a mouse model of *LMNA* dilated

 *8-16 weeks 16-20 weeks* 

(mm) EF (%) n LVEDD

*Lmna*+/+ 13 3.3 ± 0.1 2.0 ± 0.1 76.8 ± 2.0 12 3.5 ± 0.1 2.1 ± 0.1 73.2 ± 1.2

(DMSO) <sup>15</sup> 3.6 ± 0.1 \* 2.7 ± 0.1\*\*\* 56.9 ± 2.9 \*\*\* 12 4.4 ± 0.1 \* 3.5 ± 0.1 \*\*\* 42.6 ± 3.6 \*\*\*

(PD98059) 7 3.1 ± 0.2 1.8 ± 0.2 ‡‡ 73.5 ± 4.7 ‡‡ 19 3.6 ± 0.1 2.4 ± 0.1 ‡‡‡ 65.5 ± 2.6 ‡‡

LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; EF,

Comparison between DMSO-treated *Lmna*H222P/H222P and *Lmna*+/+ mice was performed using Student

Comparison between PD98059-treated *Lmna*H222P/H222P and DMSO-treated *Lmna*H222P/H222P mice was

Table 1. Echocardiographic data for *Lmna*+/+ mice and *Lmna*H222P/H222P mice treated with vehicle (DMSO) or MEK1/2 inhibitor (PD98059) between 8-16 weeks of age and 16-20 weeks

In the field of target identification there has been a great deal of enthusiasm for identifying novel drug targets based on knowledge of key signal transduction components and their link to human disease. As signaling disorders represent a major cause for the pathological states and as most of the recently validated target molecules of drug research are signal transduction kinases, signal transduction therapy has become one of the most important areas of drug research (Keri et al. 2006, Levitzki 1996). Approximately 25% of the druggable genome consists of kinases involved in signal transduction. However, only a handful of kinases inhibitors are being used in clinical practice (Margutti & Laufer 2007). This remains then a wide perspective for drug discovery. The common feature conserved throughout the entire protein kinase family is the catalytic domain. The chemical activity of a kinase involves removing a phosphate group from ATP and covalently attaching it to a free hydroxyl group. Most kinases act on both serine and threonine, others act on tyrosine, and a number act on all three (dual-specificity kinases), like MEK1/2. The fact that kinases share a highly homologous catalytic domain, and the common co-substrate ATP, initially led to the assumption that protein kinases constitute a non-druggable family of protein kinases. A

(mm)

LVESD

(mm) EF (%)

cardiomyopathy, (Figure 1).

Values are means ± standard errors.

unpaired t-test, \**P*<0.05, \*\*\**P*<0.0005.

**7. MEK1/2 inhibitors** 

(Treatment) <sup>n</sup> LVEDD (mm) LVESD

performed using Student unpaired t-test, ##*P*<0.005, ###*P*<0.0005.

Genotype

*Lmna*H222P/H222P

*Lmna*H222P/H222P

ejection fraction.

of age.

The MAPKs are activated by protein kinase cascades comprising at least three enzymes acting in series. ERK are activated directly by ERK kinases (MEK), which are dual specificity protein kinases that generally recognize only certain MAPKs as substrates. MEK are activated by MEK kinases, a structurally diverse group of kinases with less predictable specificities. MEK1/2, which activate ERK1/2, have very narrow substrate specificity. It is assumed, from lack of evidence to the contrary, that ERK1/2 are the only substrates of MEK1/2. Activated ERK1/2 kinases phosphorylate and activate a variety of substrates. All these substrates can be categorized into several groups including: transcription factors (Atf2, Elk1, c-Fos…), protein kinases and phosphatases (FAK1, MLCK, PAK1,…), cytoskeletal and scaffold proteins (dystrophin, Tau, Synaptin…), receptors and signaling molecules (EGFR, PLCg,…) and apoptosis-related proteins (Bad, Calpain, caspase 9, …). Some of the substrates can be found in the cytosol (paxilin, calnexin…), in agreement with the role of ERK1/2 in the regulation of both cytosolic and nuclear processes

### **6. Pharmacological therapy**

Because we found abnormal activation of ERK1/2 signaling pathway in hearts of *Lmna*  H222P mice, we hypothesized that pharmacological inhibition of this signaling pathway would prevent the cardiac deterioration. We treated *Lmna* H222P mice with PD098059, a tool compound that inhibits MEK1/2. We administered PD098059 or placebo (dimethylsulfoxide; DMSO) (daily, intraperitoneal injection) to *Lmna* H222P mice. We first treated male *Lmna* H222P mice starting at 8 weeks of age, prior to the onset of clinically detectable cardiac abnormalities, and analyzed them at 16 weeks (Muchir et al. 2009). Pathological dilatation of the cardiac left ventricle is often associated with fibrosis, and reactivation of a fetal gene expression program characterized by increased levels of atrial natriuretic peptide, brain natriuretic peptide, and -myosin light and heavy chains. Accordingly, in hearts from untreated *Lmna* H222P mice and those treated with vehicle (DMSO), expression of mRNAs encoding natriuretic peptide precursors as well as mRNAs encoding myosin light chains were significantly increased. We showed that after treatment with PD098059, the cardiac expression of these mRNAs was significantly lowered compared to vehicle-treated *Lmna* H222P mice (Muchir et al. 2009). Similarly, we also demonstrated that *Lmna* H222P mice treated with PD98059 had a lower degree of cardiac fibrosis than the *Lmna* H222P mice treated with the vehicle. After 8 weeks of treatment with DMSO or PD98059 *Lmna* H222P mice were anesthetized and the cardiac dimensions and function measured by cardiac ultrasound. M-mode transthoracic echocardiography showed increased left ventricle end-diastolic diameter and left ventricle end-systolic diameter in *Lmna* H222P mice treated with DMSO compared with control mice. *Lmna* H222P mice treated with PD98059 had significantly smaller left ventricle end-systolic diameters compared to the DMSO-treated mice (Table 1). Cardiac fractional shortening and ejection fraction were reduced in *Lmna* H222P mice compared to control mice but increased in the *Lmna*  H222P mice treated with PD98059.

As treatment of cardiomyopathy in human subjects may more likely be administered after the onset of symptoms or detectable cardiac abnormalities, we next treated mice with PD98059 starting at 16 weeks of age, when male *Lmna* H222P mice have left ventricular dilatation and an ejection fraction approximately 70 percent that of wild type mice, and analyzed the mice at 20 weeks (Wu et al. 2011). Treatment with PD98059 prevented left ventricular end-systolic dilatation, increased ejection fraction (Table 1), blocked increased cardiac expression of RNAs encoding natriuretic peptide precursors and reversed the induction of elements of the "fetal gene program" compared to placebo-treated mice. As significant cardiac fibrosis occurs in end-stage dilated cardiomyopathy, particularly *LMNA*  dilated cardiomyopathy, we also examined cardiac fibrosis after treatment. *Lmna* H222P mice treated with PD98059 had a lower degree of cardiac fibrosis than the *Lmna* H222P mice treated with placebo. Overall, this work showed that inhibiting ERK1/2 signaling had positive effects on cardiac biochemistry and physiology in a mouse model of *LMNA* dilated cardiomyopathy, (Figure 1).


LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; EF, ejection fraction.

Values are means ± standard errors.

100 Advances in Protein Kinases

The MAPKs are activated by protein kinase cascades comprising at least three enzymes acting in series. ERK are activated directly by ERK kinases (MEK), which are dual specificity protein kinases that generally recognize only certain MAPKs as substrates. MEK are activated by MEK kinases, a structurally diverse group of kinases with less predictable specificities. MEK1/2, which activate ERK1/2, have very narrow substrate specificity. It is assumed, from lack of evidence to the contrary, that ERK1/2 are the only substrates of MEK1/2. Activated ERK1/2 kinases phosphorylate and activate a variety of substrates. All these substrates can be categorized into several groups including: transcription factors (Atf2, Elk1, c-Fos…), protein kinases and phosphatases (FAK1, MLCK, PAK1,…), cytoskeletal and scaffold proteins (dystrophin, Tau, Synaptin…), receptors and signaling molecules (EGFR, PLCg,…) and apoptosis-related proteins (Bad, Calpain, caspase 9, …). Some of the substrates can be found in the cytosol (paxilin, calnexin…), in agreement with the role of

Because we found abnormal activation of ERK1/2 signaling pathway in hearts of *Lmna*  H222P mice, we hypothesized that pharmacological inhibition of this signaling pathway would prevent the cardiac deterioration. We treated *Lmna* H222P mice with PD098059, a tool compound that inhibits MEK1/2. We administered PD098059 or placebo (dimethylsulfoxide; DMSO) (daily, intraperitoneal injection) to *Lmna* H222P mice. We first treated male *Lmna* H222P mice starting at 8 weeks of age, prior to the onset of clinically detectable cardiac abnormalities, and analyzed them at 16 weeks (Muchir et al. 2009). Pathological dilatation of the cardiac left ventricle is often associated with fibrosis, and reactivation of a fetal gene expression program characterized by increased levels of atrial natriuretic peptide, brain natriuretic peptide, and -myosin light and heavy chains. Accordingly, in hearts from untreated *Lmna* H222P mice and those treated with vehicle (DMSO), expression of mRNAs encoding natriuretic peptide precursors as well as mRNAs encoding myosin light chains were significantly increased. We showed that after treatment with PD098059, the cardiac expression of these mRNAs was significantly lowered compared to vehicle-treated *Lmna* H222P mice (Muchir et al. 2009). Similarly, we also demonstrated that *Lmna* H222P mice treated with PD98059 had a lower degree of cardiac fibrosis than the *Lmna* H222P mice treated with the vehicle. After 8 weeks of treatment with DMSO or PD98059 *Lmna* H222P mice were anesthetized and the cardiac dimensions and function measured by cardiac ultrasound. M-mode transthoracic echocardiography showed increased left ventricle end-diastolic diameter and left ventricle end-systolic diameter in *Lmna* H222P mice treated with DMSO compared with control mice. *Lmna* H222P mice treated with PD98059 had significantly smaller left ventricle end-systolic diameters compared to the DMSO-treated mice (Table 1). Cardiac fractional shortening and ejection fraction were reduced in *Lmna* H222P mice compared to control mice but increased in the *Lmna* 

As treatment of cardiomyopathy in human subjects may more likely be administered after the onset of symptoms or detectable cardiac abnormalities, we next treated mice with PD98059 starting at 16 weeks of age, when male *Lmna* H222P mice have left ventricular dilatation and an ejection fraction approximately 70 percent that of wild type mice, and

ERK1/2 in the regulation of both cytosolic and nuclear processes

**6. Pharmacological therapy** 

H222P mice treated with PD98059.

Comparison between DMSO-treated *Lmna*H222P/H222P and *Lmna*+/+ mice was performed using Student unpaired t-test, \**P*<0.05, \*\*\**P*<0.0005.

Comparison between PD98059-treated *Lmna*H222P/H222P and DMSO-treated *Lmna*H222P/H222P mice was performed using Student unpaired t-test, ##*P*<0.005, ###*P*<0.0005.

Table 1. Echocardiographic data for *Lmna*+/+ mice and *Lmna*H222P/H222P mice treated with vehicle (DMSO) or MEK1/2 inhibitor (PD98059) between 8-16 weeks of age and 16-20 weeks of age.

### **7. MEK1/2 inhibitors**

In the field of target identification there has been a great deal of enthusiasm for identifying novel drug targets based on knowledge of key signal transduction components and their link to human disease. As signaling disorders represent a major cause for the pathological states and as most of the recently validated target molecules of drug research are signal transduction kinases, signal transduction therapy has become one of the most important areas of drug research (Keri et al. 2006, Levitzki 1996). Approximately 25% of the druggable genome consists of kinases involved in signal transduction. However, only a handful of kinases inhibitors are being used in clinical practice (Margutti & Laufer 2007). This remains then a wide perspective for drug discovery. The common feature conserved throughout the entire protein kinase family is the catalytic domain. The chemical activity of a kinase involves removing a phosphate group from ATP and covalently attaching it to a free hydroxyl group. Most kinases act on both serine and threonine, others act on tyrosine, and a number act on all three (dual-specificity kinases), like MEK1/2. The fact that kinases share a highly homologous catalytic domain, and the common co-substrate ATP, initially led to the assumption that protein kinases constitute a non-druggable family of protein kinases. A

MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by *LMNA* Mutations 103

Several allosteric MEK1/2 inhibitors are in clinical and pre-clinical development. Some of

CI-1040 (PD184352), a benzhydroxamate from Pfizer, was the first small-molecule MEK1/2 inhibitor that proceeded to clinical testing. It was developed based on compounds and structures identified during the screening that led to the identification of PD098059, but had improved potency and selectivity (Barrett et al. 2008). Cl-1040 is an oral MEK1/2 inhibitor with promising pre-clinical activity that led to its clinical development (Sebolt-Leopold et al. 1999). It underwent phase I testing in 77 patients with advanced solids tumors (LoRusso et al. 2005). CI-1040 was well tolerated with no grade IV toxicities and only a limited number of grade III toxicities. The majorities of toxicities (98%) were grade I/II and included diarrhea (43%), fatigue (30%), rash (18%) and nausea (16%). Antitumor activity was seen in 1 pancreatic cancer patient who had a partial response lasting 12 months. Nineteen (25%) subjects had stable disease for 3 months, and this observation was commonly associated with symptomatic benefit. On the basis of these results, a multicenter, parallel arm phase II study of CI-1040 was performed in patients with advanced breast, colon, pancreatic, and non-small cell lung cancer. CI-1040 was relatively well tolerated, with 19% experiencing grade III toxicities and no patients having grade IV toxicities. The toxicities included diarrhea, nausea, fatigue, rash, edema, abdominal pain, anorexia, and facial edema. However, no patients had a partial or complete response and the trial was closed. It appears

PD0325901 is a second-generation oral MEK1/2 inhibitor subsequently developed by Pfizer. Relatively minor changes distinguish the chemical structure of PD0325901 from that of CI-1040. The cyclopropylmethoxy group of CI-1040 was replaced with a R-dihydroxy-propoxy group and the 2-chloro substituent of CI-1040 was replaced with a 2-fluoro group on the second aromatic ring. Nevertheless, these minor structural changes imparted significant increases in potency with PD0325901 (Brown et al. 2007). Pre-clinical findings of significantly improved pharmacologic and pharmaceutical properties of PD0325901 were determined to hold promise for the use of the compound as a therapeutic agent. The first-inhuman trial of PD0325901 employed an open-label, dose-escalating design in 41 patients with advanced colon, melanoma, and non-small cell lung cancer. Adverse events were observed, including rash (49%), diarrhea (49%), fatigue (34%), visual disturbance (34%), nausea (29%), edema (29%), pruritus (14%), anemia (11%) and dyspepsia (11%). The compound underwent a phase II testing in patients with advanced colon, melanoma and non-small cell lung cancer. More concerns have been focused on neurologic adverse event (confusion and hallucination) in three patients observed in the first trial, leading to putting a halt on the human trials using PD0325901. It is unclear if the drug caused these adverse

ARRY-142886/AZD6244/selumetinib (Array Biopharma/AstraZeneca) is a potent, highly specific MEK1/2 inhibitor. ARRY-142886/AZD6244 has undergone phase I testing in a trial of 57 patients with solid tumors. Hypoxia, rash, diarrhea, nausea, fatigue and blurred vision have been documented as the most common treatment-related toxicities in this study (grade I to III). Thirty-nine patients completed the study and 19 of them had stabilization of their disease after the treatment, 9 remained stable for five or more months. These promising

results triggered a phase II study, which is currently under investigation.

the MEK1/2 inhibitors that have been used in human subjects include:

that CI-1040 will not be further developed in these tumor types.

events.

Fig. 1. Study from *Lmna*H222P/H222P mice suggests that activation of ERK1/2 underlies the development of *LMNA* dilated cardiomyopathy. *Lmna*H222P/H222P mice develop cardiac chamber dilation and decreased left ventricle ejection fraction. Affymetrix approach showed that ERK1/2 signaling pathways is abnormally activated in the heart of *Lmna*H222P/H222P mice compared to *Lmna*+/+ mice, before any detectable sign of cardiac deterioration. Pharmacological intervention using PD98059, an inhibitor of MEK1/2, the kinase that activate ERK1/2, improves the cardiac function of *Lmna*H222P/H222P mice.

type of inhibitor, allosteric (non-ATP competitive), could potentially solve the selectivity issues related to protein kinase inhibition. PD098059 (Dudley et al. 1995) and U0126 (Favata et al. 1998) were among the first specific MEK1/2 allosteric inhibitors described. Although they have been extremely useful in the in vitro study of MAPK signaling, they have not been pursued in clinical development because of poor pharmacologic characteristics.

Fig. 1. Study from *Lmna*H222P/H222P mice suggests that activation of ERK1/2 underlies the development of *LMNA* dilated cardiomyopathy. *Lmna*H222P/H222P mice develop cardiac chamber dilation and decreased left ventricle ejection fraction. Affymetrix approach showed that ERK1/2 signaling pathways is abnormally activated in the heart of *Lmna*H222P/H222P mice

type of inhibitor, allosteric (non-ATP competitive), could potentially solve the selectivity issues related to protein kinase inhibition. PD098059 (Dudley et al. 1995) and U0126 (Favata et al. 1998) were among the first specific MEK1/2 allosteric inhibitors described. Although they have been extremely useful in the in vitro study of MAPK signaling, they have not been

compared to *Lmna*+/+ mice, before any detectable sign of cardiac deterioration. Pharmacological intervention using PD98059, an inhibitor of MEK1/2, the kinase that

pursued in clinical development because of poor pharmacologic characteristics.

activate ERK1/2, improves the cardiac function of *Lmna*H222P/H222P mice.

Several allosteric MEK1/2 inhibitors are in clinical and pre-clinical development. Some of the MEK1/2 inhibitors that have been used in human subjects include:

CI-1040 (PD184352), a benzhydroxamate from Pfizer, was the first small-molecule MEK1/2 inhibitor that proceeded to clinical testing. It was developed based on compounds and structures identified during the screening that led to the identification of PD098059, but had improved potency and selectivity (Barrett et al. 2008). Cl-1040 is an oral MEK1/2 inhibitor with promising pre-clinical activity that led to its clinical development (Sebolt-Leopold et al. 1999). It underwent phase I testing in 77 patients with advanced solids tumors (LoRusso et al. 2005). CI-1040 was well tolerated with no grade IV toxicities and only a limited number of grade III toxicities. The majorities of toxicities (98%) were grade I/II and included diarrhea (43%), fatigue (30%), rash (18%) and nausea (16%). Antitumor activity was seen in 1 pancreatic cancer patient who had a partial response lasting 12 months. Nineteen (25%) subjects had stable disease for 3 months, and this observation was commonly associated with symptomatic benefit. On the basis of these results, a multicenter, parallel arm phase II study of CI-1040 was performed in patients with advanced breast, colon, pancreatic, and non-small cell lung cancer. CI-1040 was relatively well tolerated, with 19% experiencing grade III toxicities and no patients having grade IV toxicities. The toxicities included diarrhea, nausea, fatigue, rash, edema, abdominal pain, anorexia, and facial edema. However, no patients had a partial or complete response and the trial was closed. It appears that CI-1040 will not be further developed in these tumor types.

PD0325901 is a second-generation oral MEK1/2 inhibitor subsequently developed by Pfizer. Relatively minor changes distinguish the chemical structure of PD0325901 from that of CI-1040. The cyclopropylmethoxy group of CI-1040 was replaced with a R-dihydroxy-propoxy group and the 2-chloro substituent of CI-1040 was replaced with a 2-fluoro group on the second aromatic ring. Nevertheless, these minor structural changes imparted significant increases in potency with PD0325901 (Brown et al. 2007). Pre-clinical findings of significantly improved pharmacologic and pharmaceutical properties of PD0325901 were determined to hold promise for the use of the compound as a therapeutic agent. The first-inhuman trial of PD0325901 employed an open-label, dose-escalating design in 41 patients with advanced colon, melanoma, and non-small cell lung cancer. Adverse events were observed, including rash (49%), diarrhea (49%), fatigue (34%), visual disturbance (34%), nausea (29%), edema (29%), pruritus (14%), anemia (11%) and dyspepsia (11%). The compound underwent a phase II testing in patients with advanced colon, melanoma and non-small cell lung cancer. More concerns have been focused on neurologic adverse event (confusion and hallucination) in three patients observed in the first trial, leading to putting a halt on the human trials using PD0325901. It is unclear if the drug caused these adverse events.

ARRY-142886/AZD6244/selumetinib (Array Biopharma/AstraZeneca) is a potent, highly specific MEK1/2 inhibitor. ARRY-142886/AZD6244 has undergone phase I testing in a trial of 57 patients with solid tumors. Hypoxia, rash, diarrhea, nausea, fatigue and blurred vision have been documented as the most common treatment-related toxicities in this study (grade I to III). Thirty-nine patients completed the study and 19 of them had stabilization of their disease after the treatment, 9 remained stable for five or more months. These promising results triggered a phase II study, which is currently under investigation.

MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by *LMNA* Mutations 105

Ben Yaou, R., Gueneau, L., Demay, L., Stora, S., Chikaoui, K., Richard, P. & Bonne, G. (2006)

Brown, A.P., Carlson, T.C.G., Loi, C.M. & Graziano, M.J. (2007) Pharmacodynamic and

Davis, R.J. (1993) The mitogen-activated protein kinase signal transduction pathway. *J Biol* 

Dechat, T., Pfleghaar, K., Sengupta, K., Shimi, T., Shumaker, D. K., Solimando, L. &

Dudley, D.T., Pang, L., Decker, S.J., Bridges, A.J. & Saltiel, A.R. (1995) A synthetic inhibitor

Favata, M.F., Horiuchi, K.Y., Manos, E.J., Daulerio, A.J., Stradley, D.A., Feeser, W.S., Van

No.9, pp.848-855, ISSN 0003-9683.

No.5, pp.671-679, ISSN 0344-5704.

No.17, pp.7686-7689, ISSN 0027-8424.

No.12, pp.1158-1160, ISSN 1099-5129.

vol.8, No.2, pp.239-44, ISSN 0955-0674.

ISSN 0890-9369.

*Chem* vol.268, No.20, pp.14553-14556, ISSN 0021-9258.

Heart involvement in lamin A/C related diseases. *Arch Mal Coeur Vaiss* vol.99,

toxicokinetics evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. *Cancer Chemother Pharmacol* vol.59,

Goldman, R. D. (2008). Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. *Genes Dev* vol.22, No.7, pp.832-853,

of the mitogen-activated protein kinase cascade. *Proc. Natl. Acad. Sci. USA* vol.92,

Dyk, D.E., Pitts, W.J., Earl, R.A., Hobbs, F., Copeland, R.A., Magola, R.L., Scherle, P.A. & Trzasko, J.M. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. *J Biol Chem* vol.273, No.29, pp.18623-18632, ISSN 0021-9258. Fisher, D. Z., Chaudhary, N. & Blobel, G. (1986) cDNA sequencing of nuclear lamins A and

C reveals primary and secondary structural homology to intermediate filament proteins. *Proc Natl Acad Sci USA* vol.83, No.17, pp.6450-6454, ISSN 0027-8424. Golzio, P.G., Chiribiri, A. & Gaita, F. (2007) "Unexpected sudden death avoided by

implantable cardioverter-defibrillator in Emery-Dreifuss patient. *Europace* vol.9,

Smoot, L., Mullen, M.P., Woolf, P.K., Wigle, E.D., Seidman, J.G. & Seidman, C.E. (2000) Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy.

Marosfalvi, J., Szabadkai, I., Pato, J., Greff, Z., Hafenbradl, D., Daub, H., Muller, G., Klebl, B. & Ullrich, A. (2006) Signal transduction therapy with rationally designed kinase inhibitors. *Curr Signal Transduct Ther* vol.1, No.1, pp.67-95, ISSN 1574-3624. Lammerding, J., Schulze, P.C., Takahashi, T., Kozlov, S., Sullivan, T., Kamm, R.D., Stewart,

C.L. & Lee, R.T. (2004) Lamin A/C deficiency causes defective nuclear mechanics and machanotransduction. *J Clin Invest* vol.113, No.3, pp.370-378, ISSN 0021-9738. Levitzki A (1996) Targeting signal transduction for disease therapy. *Curr Opin Cell Biol.*

Hill, R., Gregoritch, J.M., Anderson, J.L., Quinones, M., Bachinski, L.L. & Roberts, R. (2001) Novel cardiac troponin T mutation as a cause of familial dilated

Kamisago, M., Sharma, S.D., DePalma, S.R., Solomon, S., Sharma, P., McDonough, B.,

Keri, G., Orfi, L., Eros, D., Hegymegi-Barakonyi, B., Szantai-Kis, C., Horvath, Z., Waczek, F.,

Li, D., Tapscoft, T., Gonzalez, O., et al. (1999) Desmin mutations responsible for idiopathic dilated cardiomyopathy. *Circulation* vol.100, No.5, pp.461-464, ISSN 0009-7322. Li, D., Czernuszewicz, G.Z., Gonzales, O., Tapscoft, T., Karibe, A., Durand, J.B., Brugada, R.,

cardiomyopathy. *Circulation* vol.104, No.18, pp.2188-2193, ISSN 0009-7322.

*N Engl J Med* vol.343, No.23, pp.1688-1696, ISSN 0028-4793.

ARRY-162, ARRY-300 and other Array MEK inhibitors (Array Biopharma/Novartis) are potent, highly specific MEK1/2 inhibitors. ARRY-162 is currently in phase I development for cancer. Previously, it failed to meet efficacy endpoints in phase II studies in rheumatoid arthritis. ARRY-162 is an orally active, potent, selective, non-ATP-competitive inhibitor of MEK 1/2.

RDEA119 (Ardea Biosciences/Bayer) is another highly selective MEK1/2 inhibitor. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system side effects. In preclinical studies, RDEA119 has demonstrated synergistic activity when used in combination with multiple anti-cancer agents in a wide range of tumor cell lines. Ardea Biosciences initiated a phase I clinical of RDEA119 trial in 60 patients with advanced cancer.

### **8. Discussion**

Less than a decade ago the kinases constituting mammalian MAPK pathways were identified through intense efforts to understand the molecular events underlying cellular responses to extracellular signals. During this decade the kinases constituting ERK1/2 signaling pathways have come to be appreciated as key cellular signal transducers and thus attractive targets for drug development. Successful drug development has required the demonstration that the difficulties presented by a large gene family with a highly conserved catalytic core could successfully be targeted with specific and potent small-molecule inhibitors. These efforts are now beginning to bear fruit with the initiation of clinical trials in multiple human diseases. It is currently unclear whether it will be efficacious in *LMNA* dilated cardiomyopathy. The relevance of pre-clinical to basic research to human clinical protocols is still relatively unclear. Nevertheless, the outcome of clinical trials of compounds inhibiting ERK1/2 signaling pathways is of significant interest to both the basic and the clinical scientific communities focusing on *LMNA* dilated cardiomyopathy. Their positive outcome would be a triumph of translating basic scientific understanding of cellular function into successful human therapies.

### **9. References**


ARRY-162, ARRY-300 and other Array MEK inhibitors (Array Biopharma/Novartis) are potent, highly specific MEK1/2 inhibitors. ARRY-162 is currently in phase I development for cancer. Previously, it failed to meet efficacy endpoints in phase II studies in rheumatoid arthritis. ARRY-162 is an orally active, potent, selective, non-ATP-competitive inhibitor of

RDEA119 (Ardea Biosciences/Bayer) is another highly selective MEK1/2 inhibitor. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system side effects. In preclinical studies, RDEA119 has demonstrated synergistic activity when used in combination with multiple anti-cancer agents in a wide range of tumor cell lines. Ardea Biosciences initiated a phase I clinical of

Less than a decade ago the kinases constituting mammalian MAPK pathways were identified through intense efforts to understand the molecular events underlying cellular responses to extracellular signals. During this decade the kinases constituting ERK1/2 signaling pathways have come to be appreciated as key cellular signal transducers and thus attractive targets for drug development. Successful drug development has required the demonstration that the difficulties presented by a large gene family with a highly conserved catalytic core could successfully be targeted with specific and potent small-molecule inhibitors. These efforts are now beginning to bear fruit with the initiation of clinical trials in multiple human diseases. It is currently unclear whether it will be efficacious in *LMNA* dilated cardiomyopathy. The relevance of pre-clinical to basic research to human clinical protocols is still relatively unclear. Nevertheless, the outcome of clinical trials of compounds inhibiting ERK1/2 signaling pathways is of significant interest to both the basic and the clinical scientific communities focusing on *LMNA* dilated cardiomyopathy. Their positive outcome would be a triumph of translating basic scientific understanding of cellular

Aebi, U., Cohn, J., Buhle, L. & Gerace, L. (1986). The nuclear lamina is a meshwork of intermediate-type filaments. *Nature* vol.323, No.6088, pp.560-564, ISSN 0028-0836. Arimura, T., Helbling-Leclerc, A., Massart, C., Varnous, S., Niel, F., Lacène, E., Fromes, Y.,

Barrett, S.D., Bridges, A.J., Dudley, D.T., Saltiel, A.R., Fergus, J.H., Flamme, C.M., Delaney,

Vol.18, No.24, pp.6501-6504, ISSN 0960-894X.

Toussaint, M., Mura, A.M., Keller, D.I., Amthor, H., Isnard, R., Malissen, M., Schwartz, K. & Bonne, G. (2005). Mouse model carrying H222P-Lmna mutation develops muscular dystrophy and dilated cardiomyopathy similar to human striated muscle laminopathies. *Hum Mol Genet* Vol.14, No.1, pp.155-169, ISSN 0964-

A.M., Kaufman, M., LePage, S., Leopold, W.R., Przybranowski, S.A., Sebolt-Leopold, J., van Becelaere, K., Doherty, A.M., Kennedy, R.M., Marston, D., Howard Jr, W.A., Smith, Y., Warmus, J.S. & Tecle, H. (2008) The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901. *Bioorg Med Chem Lett.*

RDEA119 trial in 60 patients with advanced cancer.

function into successful human therapies.

MEK 1/2.

**8. Discussion** 

**9. References** 

6906.


MEK1/2 Inhibitors to Treat Dilated Cardiomyopathy Caused by *LMNA* Mutations 107

Olson, T.M., Michels, V.V., Thibodeau, S.N., Tai, Y.S. & Keating, M.T. (1998) Actin mutations

Olson, T.M., Kishimoto, N.Y., Whitby, F.G., & Michels, V.V. (2001) Mutations that alter the

Tan, W., DePrimo, S., Krishnamurthi, S.S. et al. (2007) Pharmacokinetic (PK) and

Taylor, M.R.G., Fain, P.R., Sinagra, G., Robinson, M.L., Robertson, A.D., Carniel, E., Di

Sanna, T., Dello Russo, A., Toniolo, D., Vytopil, M., Pelargonio, G., De Martino, G., Ricci, E.,

Sebolt-Leopold, J.S., Dudley, D.T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R.C.,

Seger, R. & Krebs, E.G. (1995) The MAPK signaling cascade. *FASEB J* vol.9, No. 9, pp.726-

Stewart, C.L., Roux, K.J. & Burke, B. (2007) Blurring the boundary: the nuclear envelope extends its reach. *Science* vol.318, No.5855, pp.1408-1412, ISSN 0036-8075. Van Berlo, J.H., de Voogt, W.G., van der Kooi, A.J., van Tintelen, J.P., Bonne, G., Ben Yaou,

Wu, W., Shan, J., Bonne, G., Worman, H.J. & Muchir, A. (2010) Pharmacological inhibition

mutations. *Eur Heart J* vol.24, No.24, pp.2227-2236, ISSN 0195-668X. Schonberger, J. & Seidman, C.E. (2001) Many roads lead to a broken heart: The genetics of

tumors in vivo. *Nat Med* vol.5, No.7, pp.810-816, ISSN 1078-8956.

*Mol Med* vol.83, No.1, pp.79-83, ISSN 1432-1440.

mutations. *J Am Coll Cardiol* vol.41, No.5, pp.771-780, ISSN 0735-1097. Tsubata, S., Bowles, K.R., Vatta, M., Zintz, C., Titus, J., Muhonen, L., Bowles, N.E. &

*Mol Cell Cardiol* vol.33, No.4, pp.723-732, ISSN 0022-2828.

pp.357-369, ISSN 0021-9738.

ISSN 0021-9738.

735, ISSN 0892-6638.

0006-3002.

9297.

No.5364, pp.750-752, ISSN 0036-8075.

vol.6, pp.3648 (abstract), ISSN 1535-7163.

Feneley, M.P. & Fatkin, D. (2004) Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. *J Clin Invest* vol.113, No.3,

in dilated cardiomyopathy, a heritable form of heart failure. *Science* vol.280,

surface charge of alpha-tropomyosin are associated with dilated cardiomyopathy. *J* 

pharmacodynamic (PD) results of a phase I study of PD-0325901, as second generation oral MEK inhibitor, in patients with advanced cancer. *Mol Cancer Ther*

Lenarda, A., Bohlmeyer, T.J., Ferguson, D.A., Brodsky, G.L., Boucek, M.M., Lascor, J., Moss, A.C., Li, W.L.P., Stetler, G.L., Muntoni, F., Bristow, M.R. & Mestroni, L. (2003) Natural history of dilated cardiomyopathy due to lamin A/C gene

Towbin, J.A. (2000) Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. *J Clin Invest* vol.106, No.5, pp.655-662,

Silvestri, G., Giglio, V., Messano, L., Zachara, E. & Bellochi, F. (2003) Cardiac features of Emery-Dreifuss muscular dystrophy caused by lamin A/C gene

dilated cardiomyopathy. *Am J Hum Genet* vol.69, No.2, pp.249-260, ISSN 0002-

Tecle, H., Barrett, S.D., Bridges, A., Przybranowski, S., Leopold, W.R., & Saltiel, A.R. (1999) Blockade of the MAP kinase pathway suppresses growth of colon

R., Duboc, D., Rossenbacker, T., Heidbuchel, H., de Visser, M., Crijns, H.J.G.M. & Pinto, Y.M. (2005) Meta-analysis of clinical characteristics of 299 carriers of *LMNA* gene mutations: de lamin A/C mutations portend a high risk of sudden death? *J* 

of c-Jun N-terminal kinase signaling prevents cardiomyopathy caused by mutation in LMNA gene. *Biochim Biophysi Acta* vol.1802, No.7-8, pp.632-638, ISSN


Lin, F., & Worman, H. J. (1993). Structural organization of the human gene encoding nuclear

LoRusso, P., Adjei, A., Varterasian, M., Gadgeel, S., Reid, J., Mitchell, D.Y., Hanson, L.,

Luk, A., Ahn, E., Soor, G.S. & Butany, J. (2009) Dilated cardiomyopathy: a review. *J Clin* 

Margutti, S. & Lauger, S.A. (2007) Are MAP kinases drug targets? Yes, but difficult ones.

Maron, B.J., Towbin, J.A., Thiene, G., Antzelevitch, C., Corrado, D., Arnett, D., Moss, A.J.,

McKeon, F. D., Kirschner, M. W. & Caput, D. (1986). Homologies in both primary and

Meune, C., Van Berlo, J. H., Anselme, F., Bonne, G., Pinto, Y. M. & Duboc, D. (2006). Primary

Michels, V.V., Moll, P., Miller, F.A, Tajik, A.J., Chu, J.S., Driscoll, D.J., Burnett, J.C.,

Muchir, A., Pavlidis, P., Decostre, V., Herron, A. J., Arimura, T., Bonne, G. & Worman, H. J.

Muchir, A., Shan, J., Bonne, G., Lehnart, S.E. & Worman, H.J. (2009) Inhibition of

Muntoni, F., Cau, M., Ganau, A., Congliu, R., Arvedi, G., Mateddu, A., Marrosu, M.G.,

cardiomyopathy. *N Engl J Med* vol.329, No.13, pp.921-925, ISSN 0028-4793. Nikolova, V., Leimena, C., McMahon, A.C., Tam, J.C., Chandar, S., Jogia, D., Kesteven, S.H.,

cardiomyopathy. *N Engl J Med* vol.326, No.2, pp.77-82, ISSN 0028-4793. Morita, H., Seidman, J. & Seidman, C.E. (2005) Genetic causes of human heart failure. *J Clin* 

Seidman, C.E. & Young, J.B. (2006) Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention *Circulation* vol.113, No.14, pp.1807-1816, ISSN 0009-

secondary structure between nuclear envelope and intermediate filament proteins.

prevention of sudden death in patients with lamin A/C gene mutations. *N Engl J* 

Rodeheffer, R.J., Chesebro, J.H. & Tazelaar, H.D. (1992) The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated

(2007). Activation of MAPK pathways links *LMNA* mutations to cardiomyopathy in Emery-Dreifuss muscular dystrophy. *J Clin Invest* vol.117, No.5, pp.1282-1293,

extracellular signal-regulated kinase signaling to prevent cardiomyopathy caused by mutation in the gene encoding A-type lamins*. Hum Mol Genet* vol.18, No.2,

Cianchetti, C., Realdi, G., Cao, A. & Melis, M.A. (1993) Brief Report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated

Michalicek, J., Otway, R., Verheyen, F., Rainer, S., Stewart, C.L., Martin, D.,

0021-9258.

7322.

ISSN 0021-9738.

pp.241-247, ISSN 0964-6906.

No.23, pp.5281-5293, ISSN 0732-183X.

*Pathol* vol.62, No.3, pp.219-225, ISSN 0002-9173.

*Chem Med Chem* vol.2, No.8, pp.1116-1140, ISSN 1860-7187.

*Nature* vol.319, No.6053, pp.463-468, ISSN 0028-0836.

*Med* vol.354, No.2, pp.209-210, ISSN 0028-4793.

*Invest* vol.115, No.3, pp.518-526, ISSN 0021-9738.

lamin A and nuclear lamin C. *J Biol Chem* vol.268, No.22, pp.16321-16326, ISSN

DeLuca, P., Bruzek, L., Piens, J., Asbury, P., Van Becelaere, K., Herrera, R., Sebolt-Leopold, J. & Meyer, M.B. (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. *J Clin Oncol* vol.23, Feneley, M.P. & Fatkin, D. (2004) Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. *J Clin Invest* vol.113, No.3, pp.357-369, ISSN 0021-9738.


**5** 

*Chile* 

**Signaling Pathways Coupled to** 

*Laboratory of Cellular Pathology, Institute of Anatomy,* 

Pamela Ehrenfeld, Carlos D. Figueroa, Kanti D. Bhoola and Carola E. Matus

**Activation of the Kinin B1 Receptor** 

*Histology and Pathology, Universidad Austral de Chile, Valdivia* 

Kinins are a group of bioactive peptides, which are formed by an endogenous enzymatic cascade consisting of precursor substrates called kininogens and the proteolytic kallikrein enzymes (kininogenases). So far, two kinin-releasing enzymes (kininogenases) have been characterized, plasma (hKB1/*LKLB1*) and tissue (hK1/*KLK1*) kallikreins (Fig. 1). Both enzymes are serine proteases that are found in glandular cells, neutrophils, and biological fluids. Kininogens are multifunctional proteins involved in cascade reactions during inflammation (Bhoola et al., 1992), and more recently in carcinogenesis (Bhoola et al., 1992; 2001; Leeb-Lundberg et al., 2005). Kinins namely bradykinin (BK) and kallidin (Lys-BK) are among the most potent pro-inflammatory vasoactive peptides generated during tissue injury and noxious stimulation. BK and Lys-BK undergo metabolic degradation at a variable rate by amino-, carboxy- and endopeptidases found in tissues and biological fluids. The most physiologically relevant enzymes are carboxypeptidase N (from plasma) and carboxypeptidase M (from cell membranes), which remove the carboxy-terminal Arg present at end of the kinin molecule, resulting in the formation of the active metabolites des-Arg9-BK (DBK) and des-Arg10-kallidin, known also as Lys-des-Arg9-BK (LDBK) (Fig. 1). Furthermore, neutral endopeptidase 24.11 (CD10, enkephalinase) and angiotensin I converting enzyme, act as dipeptidyl carboxypeptidases by removing the dipeptide Phe8- Arg9 from the carboxy terminus end of BK or Lys-BK (Couture et al., 2004). It is important to mention that endopeptidase 24.15 and angiotensin I converting enzyme cleave the dipeptide Ser6-Pro7 from bradykinin 1-7 (BK1-7) to produce bradykinin 1-5 (BK1-5), one of the final metabolites of BK and DBK that possesses the longer half-life of this peptide family. The half-life of kinins depends on the rate and site of destruction, most rapid in the circulation, but less so in the extracellular fluid space and by cells. Actually, in plasma the half-life of BK and LDBK is short (15 to 20 sec) whereas BK1-5, considered in the past an inactive fragment, is considered to have a half-life of 86 to 101 min (Shima et al., 1992; Murphey et al., 2000;

Kinins are positively charged peptides that influence tissues and cells by stimulating two pharmacologically distinct G protein-coupled receptors (GPCRs). Kinin receptors are

**1. Introduction** 

2006; Morinelli et al., 2002).

**1.1 The field of kinins and their receptors** 

